A study in this context is the tumor-targeted activatable Photo-Immunotherapy (taPIT) using the FDA approved anti-epidermal growth factor receptor (EGFR) antibody (Cetuximab; Cet) conjugated with the PS; BPD in self-quenching ratios [198, 208], evaluated in preclinical models of ovarian cancer micro-metastasis. This evidence concerns the gene EGFR and neoplasm.